The LICR Melbourne-Austin Branch employs over 80 staff and primarily undertakes clinical and translation research as well as conducting basic laboratory research that supports our clinical trial activities.

The Austin Branch is currently exploring three separate cancer treatment modalities: cancer vaccines, targeted antibodies, and small molecule inhibitors. These targeted therapies are designed to prevent the growth of tumours and the spread of cancer, without the dangerous and unpleasant side effects of current cancer therapies.

Fundamental laboratory investigations are integrated with translational research, which is crucial to our ability to take scientific discoveries from the laboratory to the clinic. The Institute takes responsibility for identifying and developing the therapeutic utility of discoveries made by its global research programs through producing its own regulatory-standard therapeutic study agents, sponsoring and conducting its own clinical trials. The LICR Melbourne-Austin Branch at Austin Health is the flagship of LICR's international clinical trials efforts.